Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.37 |
| ▸ | CCNC | P24863 | 5/20 | 0.36 |
| ▸ | CDK8 | P49336 | 5/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480460 | 0.83 | CCNC (0.38) | HRH4CCNCCDK8SYKCDK2 | |
| SCHEMBL9893112 | 0.81 | HRH4 (0.38) | HRH4HRH3CCNCCDK8SYK | |
| SCHEMBL9103207 | 0.79 | ITGB2 (0.41) | HRH4HRH3CCNCCDK8SYK | |
| SCHEMBL9891837 | 0.76 | GPR119 (0.38) | — | |
| SCHEMBL9891831 | 0.76 | SORD (0.46) | HRH4HRH3 | |
| SCHEMBL9891836 | 0.75 | ACACB (0.43) | — | |
| SCHEMBL9892047 | 0.72 | CNR2 (0.47) | CYP2C9 | |
| SCHEMBL15360084 | 0.70 | HRH4 (0.54) | HRH4HRH3CCNCCDK8 | |
| SCHEMBL15360082 | 0.70 | HRH4 (0.50) | HRH4HRH3CCNCCDK8 | |
| SCHEMBL9891828 | 0.68 | MAPT (0.43) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HRH4 128/4885HRH3 236/4885CCNC 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.